NCT01218685 - Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants | Biotech Hunter

Enrollment

1,152

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

April 30, 2011

Conditions

Immunocompromised PatientsSafety of Pandemic Influenza A (H1N1)VaccineImmunogenicity of Pandemic Influenza A (H1N1)Vaccine

Interventions

BIOLOGICAL

Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS

1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.

Trial Locations (1)

05503-900

Avenida Vital Brasil 1500, São Paulo